New York, New York - July 30, 2012 - Investorideas.com, an investor
research portal specializing in sector research including biotech and
pharma stocks, issues CFA commentary by Patrick J. Murphy of Murphy
Analytics LLC on Sunshine Biopharma Inc. (
OTCBB: SBFM) and its lead anti-cancer compound, Adva-27a.
| Select Stock Trading Data |
| Recent Stock Price: |
$0.34 |
| Shares Outstanding: |
48.7 million |
| Float |
13.9 million |
| Recent Market Cap: |
$16.8 million |
| 52 Week Range: |
$0.12 - $1.45 |
| Exchange: |
OTCBB |
| Ticker: |
SBFM |
| URL: |
http://www.sunshinebiopharma.com |
| Data sourced from Yahoo! Finance; otcbb.com; Company filings |
Sunshine Bipharma, Inc. (SBFM) is focused on the research,
development and commercialization of drugs for the treatment of various
forms of cancer. SBFM reports that the preclinical studies for the
Company's lead compound, Adva-27a, a multi-purpose anti-tumor compound,
were successfully completed in late 2011. SBFM is now continuing the
clinical development of Adva-27a by conducting the next sequence of
steps comprised of GMP manufacturing, IND-enabling studies, regulatory
filing and Phase I clinical trials. SBFM plans to conduct Phase I
clinical trials for Adva-27a at the Jewish General Hospital, Montreal,
Canada, one of McGill University's Hospital Centers.
The planned indication will be multidrug resistant breast cancer as
SBFM reports that Adva-27a has shown remarkably strong cytotoxic
activity against this type of cancer. In addition, on June 26, 2012,
SBFM announced the completion of another cytotoxicity study in which
Adva-27a was found to be significantly more effective at killing
multidrug resistant small-cell lung cancer (SCLC) cells than etoposide, a
drug commonly used currently for treating SCLC.
SBFM has licensed its technology on an exclusive basis from
Advanomics Corporation and is planning to initiate its own research and
development program as soon as practicable
An article in nature biotechnology summarizes the challenge multidrug resistance creates for developing effective treatments:
"Multidrug resistance, the principal mechanism by which many
cancers develop resistance to chemotherapy drugs, is a major factor in
the failure of many forms of chemotherapy. It affects patients with a
variety of blood cancers and solid tumors, including breast, ovarian,
lung, and lower gastrointestinal tract cancers. Tumors usually consist
of mixed populations of malignant cells, some of which are
drug-sensitive while others are drug-resistant. Chemotherapy kills
drug-sensitive cells, but leaves behind a higher proportion of
drug-resistant cells. As the tumor begins to grow again, chemotherapy
may fail because the remaining tumor cells are now resistant."
As explained in an article published by the National Institutes of
Health (NIH), this cellular response to toxins in the environment is
critical for our survival and has evolved over time:
"Toxins in the environment are a major threat to many living
organisms. Once internalized, toxic compounds must be removed for the
organisms to survive. Therefore, humans have developed, inherited and
perfected ways to reduce the effect of xenobiotics. At the cellular
level, the cell membrane acts as a physical barrier to prevent compounds
from entering the cell. However, because some compounds can diffuse
through the cell membrane, alternative protective methods have evolved.
One of the most important defense mechanisms is to pump xenobiotics out
of the cells. Thus, drug transporters are commonly found in the cell
membranes of many organisms, from bacteria to mammals, and are
responsible for cell protection. However, the existence of these drug
transporters often hinders the use of compounds used to treat diseases
because they are substrates of these efflux pumps either by affecting
the pharmacokinetics of drugs in the body or by limiting accumulation in
target cells such as cancer cells."
SBFM reports that Adva-27a can overcome two of these xenobiotic
pumps - multidrug resistant transporter proteins MDR1 and MRP1, which
facilitate multidrug resistance, and as the NIH article notes, MDR1 in
particular has become the most studied gene in the field of multidrug
resistance.
In terms of gauging the potential market opportunity for Adva-27a
for use in the treatment of breast cancer, Roche's Herceptin® reached
$5.3 billion a year in sales in 2011. Herceptin® is approved for the
treatment of early-stage breast cancer that is Human Epidermal growth
factor Receptor 2-positive (HER2+), which the National Cancer Institute
estimates represents only 15% - 20% of breast cancer patients. The
American Cancer Society estimates that in the U.S. alone, there will be
229,060 new cases of breast cancer diagnosed in 2012, with 39,920 deaths
from breast cancer during the year. Given that Herceptin® revenue grew
by 9% in 2011 and has risen over 30% since 2006, it seems clear there is
a very significant market opportunity for a drug that is effective for
the non-HER2+ breast cancer population, which represents a significant
majority of breast cancer patients.
As reference for the potential market opportunity for Adva-27a for
treatment of small-cell lung cancer, the American Cancer Society
estimates there will be 226,160 new cases of lung and bronchus cancer in
the U.S. in 2012, with an estimated 160,340 deaths. The National Cancer
Institute (NCI) estimates that small-cell lung cancer (SCLC)
accounts
for approximately 15% of bronchogenic carcinomas. While etoposide, now
available as a generic, is used in combination with other medications to
treat SCLC, the NCI addresses the challenge and urgency of developing a
more effective treatment for SCLC, noting that:
"Regardless of stage, the current prognosis for patients with
SCLC is unsatisfactory despite improvements in diagnosis and therapy
made during the past 25 years. Without treatment, SCLC has the most
aggressive clinical course of any type of pulmonary tumor, with median
survival from diagnosis of only 2 to 4 months."
"For most patients with small cell lung cancer, current
treatments do not cure the cancer. If lung cancer is found, patients
should think about taking part in one of the many clinical trials being
done to improve treatment. Clinical trials are taking place in most
parts of the country for patients with all stages of small cell lung
cancer."
In a recent interview, SBFM CFO Camile Sebaaly noted that the
Company expects the first clinical trial of Adva-27a will be done on
breast cancer volunteers at Jewish General Hospital. As the Company
continues to do the work and raise the capital necessary to bring its
drug to market, Mr. Sebaaly stated that the Company expects that if FDA
approval is obtained, SBFM may have a similar sales profile to other
important cancer drugs that have reached $1 billion in sales within 2
years of FDA approval.
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider
of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly
20 years of capital markets experience providing institutional
investment and transaction analysis across a range of asset classes
including microcap equities, commercial real estate debt and equity,
municipal derivatives and public
finance,
venture capital, fixed income, CMBS and mortgage REIT's. In addition to
his work with Murphy Analytics, Mr. Murphy also serves as a consultant
to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of
the University of Notre Dame (1991), with an undergraduate degree in
Economics, and earned a Masters Degree in Finance from St. Louis
University in 1997. Mr. Murphy is a CFA Charterholder and a member of
the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for
information purposes and should not to be construed as an offer to sell
or the solicitation of an offer to buy any security. The views expressed
herein are based upon the author's analysis of the issuer's public
disclosures, and assumes both their accuracy and completeness. The
opinions and statements included herein are based on sources (including
the companies discussed and public sources) believed to be reliable and
in good faith, but no representation or warranty, express or implied, is
made as to their accuracy, completeness or correctness. The author has
not independently verified the information contained herein. This
information is not intended to be used as the sole basis of any
investment decisions,
nor should it be construed as advice designed to meet the investment
needs of any particular investor. You should review a complete
information package on all companies, which should include, but not be
limited to, the Company's annual report, quarterly reports, press
releases and all regulatory filings. The foregoing discussion contains
statements which are based on current expectations, estimates and
projections, and differences from such expectations, estimates and
projections can be expected. The author, Patrick Murphy, was compensated
$510 by InvestorIdeas.com for writing this article. Murphy does not own
shares of any of the companies mentioned in this article. Mr. Murphy's
research firm, Murphy Analytics, may be engaged for the provision of a
research report on the Company in the future.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the
research, development and commercialization of drugs for the treatment
of various forms of cancer. The Company's lead compound, Adva-27a
targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector,
including biotech and pharma stocks. Visit the biotech portal within
Investor Ideas:
www.biotechindustrystocks.com
Follow Investorideas.com on Twitter
http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Visit the SBFM profile http://www.investorideas.com/CO/SBFM/
Disclaimer/ Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell
products or securities. This site is currently compensated by featured
companies, news submissions and online advertising. Disclosure: A third
party on behalf of SBFM compensated Investorideas.com for news release
publishing and distribution: one hundred thousand 144 shares for three
months starting June 26 th/
Patrick Murphy was compensated five hundred dollars for the CFA commentary article
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source -
www.Investorideas.com
Full news:
What the analysts say: